Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
CEQUA’s nanomicellar (NCELL) technology improves the bioavailability and physicochemical stability of cyclosporine to increase ocular tissue penetration
The product is expected to be available in a week’s time
It is the first approved generic and is eligible for 180 days of Competitive Generic Therapy exclusivity
While industry steps out of its comfort zone to innovate, the government has to support by allocating funds across research lifecycle and offer incentives for innovation
Sun Pharma has reported consolidated financial results for the period ended September 30, 2021.
It is the first U.S. FDA approved novel topical mechanism for acne in nearly 40 years
In India, MSD has signed non-exclusive licensing agreements with eight pharma companies.
A long waiting period for critical equipment and a 50% hike in the cost of APIs imported from China are among the immediate challenges
Subscribe To Our Newsletter & Stay Updated
